Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer

Published:2020-08 Issue: Volume:146 Page:23-29
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Jung Hyun Ae,Noh Jae Myoung,Sun Jong-Mu,Lee Se-Hoon,Ahn Jin Seok,Ahn Myung-Ju,Pyo Hongryull,Ahn Yong Chan,Park Keunchil

Funder

National Research Foundation of Korea

Ministry of Science and ICT

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Cancer treatment and survivorship statistics, 2019;Miller;CA Cancer J. Clin.,2019

2. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410;Curran;J. Natl. Cancer Inst.,2011

3. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer;Furuse;J. Clin. Oncol.,1999

4. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504;Gandara;J. Clin. Oncol.,2003

5. EGFR mutation is associated with short progression-free survival in patients with stage III non-squamous cell lung cancer treated with concurrent chemoradiotherapy;Park;Cancer Res. Treat.,2019

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy;Biomarker Research;2024-09-04

2. Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials;Cancer Treatment Reviews;2024-09

3. Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: Insights from Real-World Data;Cancer Research and Treatment;2024-07-15

4. Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR);Radiotherapy and Oncology;2024-07

5. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;International Journal of Radiation Oncology*Biology*Physics;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3